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Pelvic organ prolapse may occur in up to 50% of parous women. A variety of 
urinary, bowel and sexual symptoms may be associated with prolapse.  
Objectives 
To determine the effects of the many different surgeries in the management of 
pelvic organ prolapse.  
Search strategy 
We searched the Cochrane Incontinence Group Specialised Trials Register 
(searched 3 May 2006) and reference lists of relevant articles. We also contacted 
researchers in the field.  
Selection criteria 
Randomised or quasi-randomised controlled trials that included surgical 
operations for pelvic organ prolapse. 
Data collection and analysis 
Trials were assessed and data extracted independently by two reviewers. Six 
investigators were contacted for additional information with five responding.  
Main results 
Twenty two randomised controlled trials were identified evaluating 2368 women.  
Abdominal sacral colpopexy was better than vaginal sacrospinous colpopexy in 
terms of a lower rate of recurrent vault prolapse (RR 0.23, 95% CI 0.07 to 0.77) 
and less dyspareunia (RR 0.39, 95% CI 0.18 to 0.86), but the trend towards a 
lower re-operation rate for prolapse following abdominal sacrocolpopexy was not 
statistically significant (RR 0.46, 95% CI 0.19 to 1.11). However, the vaginal 
sacrospinous colpopexy was quicker and cheaper to perform and women had an 
earlier return to activities of daily living. The data were too few to evaluate other 
clinical outcomes and adverse events. The three trials contributing to this 
comparison were clinically heterogeneous.  
For the anterior vaginal wall prolapse, standard anterior repair was associated 
with more recurrent cystoceles than when supplemented by polyglactin mesh 
inlay (RR 1.39, 95% CI 1.02 to 1.90) or porcine dermis mesh inlay (RR 2.72, 95% 
CI 1.20 to 6.14), but data on morbidity, other clinical outcomes and for other 
mesh or graft materials were too few for reliable comparisons.  
For posterior vaginal wall prolapse, the vaginal approach was associated with a 
lower rate of recurrent rectocele and/or enterocele than the transanal approach 
(RR 0.24, 95% CI 0.09 to 0.64), although there was a higher blood loss and 
postoperative narcotic use. However, data on the effect of surgery on bowel 
symptoms and the use of polyglactin mesh inlay or porcine small intestine graft 
inlay on the risk of recurrent rectocele were insufficient for meta-analysis. 
Meta-analysis on the impact of pelvic organ prolapse surgery on continence 
issues was limited and inconclusive, although about 10% of women developed 
new urinary symptoms after surgery. Although the addition of tension-free vaginal 
tape to endopelvic fascia plication (RR 5.5, 95% CI 1.36 to 22.32) and Burch 
colposuspension to abdominal sacrocolpopexy (RR 2.13, 95% CI 1.39 to 3.24) 
were followed by a lower risk of women developing new postoperative stress 
incontinence, but other outcomes, particularly economic, remain to be evaluated.  
Authors' conclusions 
Abdominal sacrocolpopexy is associated with a lower rate of recurrent vault 
prolapse and dyspareunia than the vaginal sacrospinous colpopexy. These 
benefits must be balanced against a longer operating time, longer time to return 
to activities of daily living and increased cost of the abdominal approach. The use 
of mesh or graft inlays at the time of anterior vaginal wall repair may reduce the 
risk of recurrent cystocele. Posterior vaginal wall repair may be better than 
transanal repair in the management of rectoceles in terms of recurrence of 
prolapse. The addition of a continence procedure to a prolapse repair operation 
may reduce the incidence of postoperative urinary incontinence but this benefit 
needs to be balanced against possible differences in costs and adverse effects. 
Adequately powered randomised controlled clinical trials are urgently needed.  
 
Background 
See full version of Cochrane Review 
 
Objectives 
To determine the effects of surgery in the management of pelvic organ prolapse 
and associated bladder, bowel and sexual function. 
The following specific comparisons were made, and trials that made other related 
comparisons were described: 
A For the management of upper vaginal prolapse (uterine and vaginal vault) 
1. Abdominal sacral colpopexy versus vaginal sacrospinous colpopexy. 
2. Vaginal hysterectomy versus uterine preservation. 
3. Vaginal hysterectomy with McCall culdoplasty versus vaginal hysterectomy 
and sacrospinous colpopexy. 
4. Vaginal McCall culdoplasty and uterosacral ligament plication versus vaginal 
sacrospinous colpopexy and repair. 
B For the management of anterior vaginal wall prolapse 
5. Anterior vaginal wall repair versus the abdominal paravaginal repair in the 
management of anterior vaginal wall prolapse. 
6. For midline cystocele defects, a traditional anterior vaginal wall repair versus 
anterior vaginal wall repair with graft reinforcement. 
C For the management of posterior vaginal wall prolapse 
7. Posterior vaginal wall repair versus a transanal repair. 
8. Posterior vaginal wall repair versus an abdominal posterior repair. 
9. Posterior vaginal wall repair versus posterior vaginal wall repair with graft 
reinforcement. 
D For the management of any type of prolapse 
10. Surgical treatment versus conservative treatment in the management of 
symptomatic pelvic organ prolapse. 
11. Surgical treatment versus mechanical devices in the management of pelvic 
organ prolapse. 
12. Open abdominal surgery versus the laparoscopic approach for the 
management of prolapse. 
13. Potential stress urinary incontinence (e.g. detected on reduction of prolapse 
prior to surgery) treated with formal continence surgery at the time of prolapse 
surgery, versus being left untreated.  
14. Use of native (no mesh) tissue versus mesh or grafts. 
15. One type of mesh / graft versus another type of mesh / graft. 




See full version of Cochrane review 
Description of studies 
Full reports of 33 potentially eligible studies were assessed, of which twenty two 
randomised controlled trials were identified on the surgical management of pelvic 
organ prolapse and met the inclusion criteria: fuller details are tabulated in the 
complete Cochrane review  
Methodological quality of included studies 
See full version of Cochrane review  
Results 
A. Upper vaginal prolapse (uterine and vaginal vault) (Comparison 01) 
Six trials provided data regarding the outcome of prolapse surgery for upper 
vaginal prolapse (Benson 1996; Culligan 2005; Lo 1998; Maher 2004; Meschia 
2004a; Roovers 2004). All the trials which used mesh used non-absorbable, 
permanent mesh except one trial in which an absorbable was compared with a 
non-absorbable mesh (Culligan 2005).  
Objective 1: abdominal sacral colpopexy versus vaginal sacrospinous 
colpopexy  
Three trials were considered to be similar enough to allow combination of data 
for comparison of abdominal sacral colpopexy and vaginal sacrospinous 
colpopexy (Benson 1996; Lo 1998; Maher 2004). Abdominal sacral colpopexy 
was better than vaginal colpopexy in terms of: 
• a lower rate of recurrent vault prolapse (3 out of 84 versus 13 out of 85; 
RR 0.23, 95% CI 0.07 to 0.77, Figure 1) (Benson 1996; Maher 2004);  
• the number of women failing to improve to Stage 2 or better (3 out of 52 
versus 13 out of 66; RR 0.29, 95% CI 0.09 to 0.97) (Lo 1998);  
• less postoperative dyspareunia (7 out of 45 versus 22 out of 61; RR 0.39, 
95% CI 0.18 to 0.86) (Benson 1996; Lo 1998; Maher 2004);  
• less postoperative stress urinary incontinence (14 out of 47 versus 28 out 
of 81, RR 0.55, 95%CI 0.32 to 0.95) (Benson 1996; Maher 2004). 
However, caution should be exercised when evaluating these data due to 
significant variation in the methodology of the two trials as described 
above. There was no statistically significant difference in reoperation rates 
for stress urinary incontinence (RR 0.6, 95% CI 0.21 to 1.73) (Benson 
1996; Lo 1998; Maher 2004);  
• The lower reoperation rate for prolapse after abdominal surgery did not 
reach statistical significance (6 out of 84 versus 14 out of 85, RR 1.46, 
95% CI 0.19 to 1.11) (Benson 1996; Maher 2004).  
 
The results for intraoperative blood loss were inconsistent in two studies with a 
mean difference of 298 ml less blood loss in the abdominal group in Lo's study 
(Lo 1998) and 33 ml more blood loss in Maher's trial (Maher 2004) (Comparison 
01.15.01). Benson did not report blood loss but the postoperative change in 
haemoglobin was not statistically different (Benson 1996).  
 
Women treated abdominally took significantly longer to present with recurrent 
prolapse (WMD for months to recurrence -10.90, 95% CI -17.12 to -4.68) in one 
trial (Benson 1996). On the other hand, the sacral (abdominal) colpopexy was 
associated with a longer operating time (WMD 21 minutes, 95% CI 12 to 30) 
(Benson 1996; Lo 1998; Maher 2004), longer time to recover (WMD 8.3 days, 
95% CI 3.9 to 12.7) (Maher 2004) and was more expensive (WMD US$1334, 
95% CI 1027 to 1641) (Benson 1996; Maher 2004) than the vaginal approach.  
 
Although the results for subjective prolapse symptoms favoured the abdominal 
group, the difference was statistically not significant (subjective failure after 
abdominal surgery: 9/84 versus 18 out of 85, RR 0.53, 95% CI 0.25 to 1.09) 
(Benson 1996, Maher 2004). On the limited evidence available, patient's 
satisfaction (RR 0.82, 95% CI 0.32 to 2.06) (Maher 2004) and objective failure at 
any site (any pelvic organ prolapse: RR 0.77, 95% CI 0.39 to 1.53,) (Maher 2004) 
were not clearly different in both groups. Although data were available for bowel 
outcomes (Comparisons 01.10 and 01.11) and adverse events (Comparison 
01.25), they were too few to provide sufficiently precise estimates to identify or 
rule out clinically important differences.  
Objective 2: vaginal hysterectomy versus uterine preservation  
In the fourth trial, Roovers compared abdominal sacral hysteropexy against 
vaginal hysterectomy and repair with vault fixation to the uterosacral-cardinal 
ligament complex (Roovers 2004). Although more women had subjective 
prolapse symptoms at one year after abdominal surgery (RR 3.2, 95% CI 1.29 to 
7.92), there was no statistically significant difference in the prolapse domain of 
the urinary distress inventory (UDI) (mean difference 4.1, 95% CI -5.4 to 13.6); 
nor the score for urinary incontinence (mean difference 6, 95% CI -2 to 14). 
However, at one year after surgery the vaginal group scored significantly better 
(lower) scores on the discomfort /pain domain (7.1, 95% CI 1.1 to 13.2), 
overactive bladder domain (8.7, 95% CI 0.5 to 16.9) and the obstructive 
micturition domain (10.3, 95% CI 0.6 to 20.1) as compared to the abdominal 
group. More women in the abdominal group required repeat prolapse repair (RR 
9.00, 95% CI 1.19 to 67.85): in the abdominal group, five women (13%) had a 
reoperation for recurrent cystocele and four women (10.5%) for recurrent uterine 
prolapse, whereas in the vaginal group only one patient required surgery in the 
first year for vaginal vault prolapse. The operating time was less for the 
abdominal group (WMD -10 minutes, 95% CI -12 to -8), possibly reflecting the 
less invasive nature of the abdominal procedure in this trial (the uterus was 
preserved in the abdominal group as opposed to removed in the vaginal group).  
In another trial, sacrospinous uterine suspension with uterine preservation was 
compared with vaginal hysterectomy (Jeng 2005). There were few reports of 
dyspareunia in either group (Comparison 01.13.03) but there were more adverse 
symptoms in the sacrospinous suspension arm, mostly due to buttock pain (RR 
4.23, 97% 1.25 to 14.25) (Jeng 2005). This trial could not be combined with the 
Roovers 2004 trial as the non-hysterectomy groups were too different (clinical 
heterogeneity).  
 
Objective 3: vaginal hysterectomy with McCall culdoplasty versus vaginal 
hysterectomy and sacrospinous colpopexy:  
No trials identified. 
Objective 4: vaginal McCall culdoplasty and uterosacral ligament plication 
versus vaginal sacrospinous colpopexy and repair:  
No trials identified. 
 
Objective 13: Potential stress urinary incontinence (e.g. detected on 
reduction of prolapse prior to surgery) treated with formal continence 
surgery at the time of prolapse surgery, versus being left untreated.  
One trial evaluated the effects of adding Burch colposuspension to abdominal 
sacrocolpopexy (Brubaker 2006). The trial was terminated early (after the first 
232 women had been randomised, but data were finally available for a total of 
322 women) because of a significant difference in the incontinence rates at 3 
months after surgery. Data were not provided for prolapse outcomes, but the 
addition of Burch colposuspension significantly decreased the incidence of stress 
urinary incontinence at 3 months after surgery (67 out of 152, 44% versus 35 out 
of 147, 24% with Burch, RR 1.85, 95% CI 1.32 to 2.6) (Brubaker 2006). However, 
the operating time was longer (MD -20 minutes, 95% CI -33 to -7) and the blood 
loss higher (MD -73 ml, 95% CI -73 to -30) (Brubaker 2006) in the Burch group.  
Objective 14: Use of native (no mesh) tissue versus mesh or grafts:  
In one trial (Meschia 2004a) the data were too few to address possible 
differences in the objective recurrence rate between a repair using the 
sacrospinous colpopexy and the posterior intravaginal (mesh) sling (0 out of 33 
versus 1 out of 33; RR 0.33, 95% CI 0.01 to 7.90, Figure 1) (Meschia 2004a). 
The operating time was 11 minutes shorter (WMD 11 minutes, 95% CI 2.8 to 
19.2) (Meschia 2004a) and blood loss less (WMD 70ml, 95% CI 56 to 84) 
(Meschia 2004a) with the intravaginal sling. Other clinical outcomes included 
dyspareunia, faecal incontinence, constipation, stress urinary incontinence, 
overactive bladder syndrome and voiding dysfunction, but the numbers were too 
few to draw conclusions. Mesh erosions occurred in 3 out of 33 (9%) women in 
the IVS group of events.  
Objective 15: One type of mesh / graft versus another type of mesh / graft:  
One trial (Culligan 2005) compared the abdominal sacral colpopexy using either 
absorbable cadaveric fascia lata graft (Tutuplast) or nonabsorbable (permanent) 
monofilament polypropylene mesh (Trelex). There were no recurrences of 
vaginal vault prolapse in either group, but the objective failure rate for recurrence 
at any other vaginal site was 14 out of 44 in the fascial graft group and 4 out of 
45 in the mesh group (RR 3.58, 95% CI 1.28 to 10.03) (Culligan 2005). There 
were no vaginal erosions in the 46 women in the fascial graft group but 2 out of 
54 women had mesh erosion in the non-absorbable mesh group. No data on 
bladder, bowel or sexual function were provided. 
 
B. Anterior vaginal wall prolapse (cystocele, urethrocele, paravaginal 
defect) (Comparison 02) 
Eleven trials included a variety of surgical procedures to treat anterior vaginal 
wall prolapse, with or without stress or occult stress urinary incontinence. (Bump 
1996a; Colombo 1996a; Colombo 1997; Colombo 2000; Meschia 2004; Sand 
2001; Weber 2001; Cervigni 2005; De Ridder 2004; Gandhi 2005; Meschia 
2007). Combination of data was possible for two sets of trials: two were 
comparable in terms of type of population (women with prolapse only) and types 
of operation (anterior repair with and without mesh) (Sand 2001; Weber 2001); 
and the other two in terms of types of operation (endopelvic fascia plication 
versus needle suspension) (Bump 1996a; Colombo 1997).  
 
Objective 5: anterior vaginal wall repair versus the abdominal paravaginal 
repair in the management of cystocele:  
No trials identified. 
 
Objective 6: for midline cystocele defects, a traditional anterior vaginal wall 
repair versus anterior vaginal wall repair with mesh reinforcement:  
Data from two small trials suggested that traditional anterior repair may be 
followed by higher objective failure rates than after polyglactin mesh 
reinforcement of anterior repair (RR 1.48, 95% CI 1.07 to 2.04, Figure 2) (Sand 
2001; Weber 2001), but data on reoperation rates were not given and 
complication rates were similar. Weber did not find significant differences in cure 
rates for cystocele between the standard cystocele repair (30%), ultralateral 
repair (46%) and standard plus polyglactin mesh inlay (42%) at mean follow up of 
24 months, but the trial was only powered to detect a 30% difference between 
the groups (Weber 2001).  
One trial (Meschia 2007) compared the anterior colporrhaphy without and with 
porcine dermis inlay (Pelvicol). The trial demonstrated at one-year follow up the 
objective failure rate of the anterior compartment was 20 out of 103 in the 
colporrhaphy group as compared to 7/98 in the porcine dermis group (RR 2.72 
95% CI 1.20 to 6.14, Figure 2) (Meschia 2007). There were no differences 
between groups in blood loss, inpatient-days, change in haemoglobin, 
postoperative voiding dysfunction and dyspareunia but all with wide confidence 
intervals. There was one porcine dermis graft rejection requiring surgical 
removal.  
Another trial (Gandhi 2005) compared the anterior colporrhaphy without or with 
Tutoplast (solvent dehydrated cadaveric fascia lata). At 13 months the objective 
and subjective failure rates of the anterior compartment were similar (23 out of 78 
and 16/76; RR 1.4, 95% CI 0.8 to 2.44, Figure 2 and 6 out of 57 and 6 out of 55; 
RR 0.96, 95% CI 0.33 to 2.81) (Gandhi 2005). Apart from urinary voiding function 
there were no other bladder, bowel or sexual function outcomes reported.  
The nature of the different mesh types in the latter two trials (Gandhi 2005; 
Meschia 2007)were considered too dissimilar to combine them in a meta-
analysis. 
Objective 15: One type of mesh / graft versus another type of mesh / graft:  
Two trials evaluated different mesh inlays (Cervigni 2005; De Ridder 2004).  
Cervigni compared Prolene Soft (n = 36) with porcine dermis (Pelvicol, n = 36) 
with a mean follow up of 8 months. The objective failure rates (calculated for 
grade two at the Baden-Walker half-way system) were similar between groups 
(14 out of 36 and 12 out of 36; RR 1.17, 95% CI 0.63 to 2.16, Figure 2) (Cervigni 
2005). Dyspareunia occurred in 11 out of 36 (30%) and 5 out of 36 (14%) (RR 
2.2, 95% CI 0.85 to 5.69) (Cervigni 2005) and mesh erosions in 3 out of 36 and 1 
out of 36 (RR 3.00, 95% CI 0.33 to 27.5)) (Cervigni 2005). Postoperative voiding 
dysfunction rates were 9 out of 36 and 5 out of 36 (RR 2.07, 95% CI 0.62 to 6.92) 
(Cervigni 2005).  
De Ridder (De Ridder) performed four-defect Raz anterior vaginal wall repairs 
and added a porcine dermis (Pelvicol) or polyglactin (Vicryl) inlay. Both mesh 
types are absorbable. Objective failure rates of the anterior compartment at 25 
months follow up were 6 out of 63 (9.5%) and 19 out of 62 (31%) respectively 
(RR 0.31, 95% CI 0.13 to 0.73, Figure 2) (De Ridder 2004). Further prolapse 
surgery had to be performed in 3 out of 63 and 9 out of 62 women (RR 0.33, 95% 
CI 0.09 to 1.16) (De Ridder 2004).  
The nature of the different types of mesh in the two trials (Cervigni 2005; De 
Ridder 2004) were considered too dissimilar to combine them in a meta-analysis. 
Other comparisons for anterior vaginal wall prolapse:  
Five other trials were identified which compared different operations for anterior 
vaginal wall prolapse or different continence procedures for women with urinary 
incontinence or occult urinary incontinence as well as anterior vaginal wall 
prolapse (Bump 1996a; Colombo 1996a; Colombo 1997; Colombo 2000; 
Meschia 2004).  
One single trial comparing anterior repair with Burch colposuspension showed 
statistically significant lower rates of cystocele recurrence (RR 0.09, 95% CI 0.01 
to 0.64, Figure 2) (Colombo 2000), but higher rates of persisting urinary 
incontinence (RR 3.39, 95% CI 1.40 to 8.22) (Colombo 2000). However, this was 
not reflected in differences in reoperation rates for either prolapse or 
incontinence (Comparisons 02.18.03 and 02.19.03) (Colombo 2000). Another 
small trial reported that more women were incontinent after endopelvic fascia 
plication than after TVT supplementing prolapse surgery (RR 9, 95% CI 1.23 to 
65.85) (Meschia 2004) but the data were too few to comment on the effect on 
prolapse or other clinical outcomes. However, there was a shorter operating time 
for the former operation (WMD -19 minutes, 95% CI -29 to -9) (Meschia 2004).  
C. Posterior vaginal wall prolapse (rectocele) (Comparison 03)  
Two small trials compared vaginal and transanal approaches to the management 
of rectoceles (Kahn 1999; Nieminen 2004), and two others examined posterior 
repair with and without mesh reinforcement (Paraiso 2006; Sand 2001). The 
most recent of these trials compared three techniques to correct posterior vaginal 
compartment prolapse (Paraiso 2006). 
 
Objective 7: posterior vaginal wall repair versus a transanal repair:  
Many of the important outcome parameters were not reported thus limiting the 
data available and the ability to perform meta-analyses. The results for posterior 
vaginal wall repair were better than for transanal repair in terms of subjective (RR 
0.36, 95% CI 0.13 to 1) (Kahn 1999; Nieminen 2004) and objective (RR 0.24, 
95% CI 0.09 to 0.64, Figure 3) (Kahn 1999; Nieminen 2004) failure rates 
(persistence of rectocele and/or enterocele). Analysing women with rectocele 
alone showed that recurrent rectocele occurred in 2 out of 39 in the vaginal group 
and 7 out of 48 following the transanal repair, a difference that did not reach 
statistical significance (RR 0.32, 95% CI 0.07 to 1.34, Figure 3) (Kahn 1999; 
Nieminen 2004). Postoperative enterocele was, however, significantly less 
common following the vaginal surgery as compared to the transanal group (RR 
0.23, 95% CI 0.07 to 0.83, Figure 3) (Kahn 1999; Nieminen 2004).  
Postoperative hospital stay was longer after vaginal surgery than after transanal 
surgery in one trial (mean difference (MD) 1 day, 95% CI 0.47 to 1.53) (Kahn 
1999) despite a shorter operating time (MD -7 minutes, 95% CI -12 to -2) (Kahn 
1999). The operating times in the other trial (Nieminen 2004) were the same for 
both groups (35 minutes). When data for operating time were combined (WMD -
3.6 minutes), there was significant heterogeneity (P = 0.07, I-squared = 69%) 
and the difference was not significant if a random effects model was used (95% 
CI -10.4 to 3.3 minutes). The vaginal approach was associated with a 
significantly higher blood loss (79 ml, 95% CI 40 to 119) (Kahn 1999; Nieminen 
2004) and postoperative narcotic use (Comparison 03.12.01, Kahn 1999) as 
compared to the transanal approach.  
Nieminen reported that the mean depth of rectocele on postoperative 
defecography was 4.13 cm in the transanal group and this was significantly 
larger than the 2.73 cm in the vaginal group (WMD -1.43, 95% CI -2.86 to 0, P = 
0.05, data not shown). Postoperative difficulties in bowel evacuation were seen in 
9 out of 31 in the vaginal group as compared to 14 out of 34 in the transanal 
group, a difference that was not significantly different (RR 0.73, 95% CI 0.37 to 
1.42) (Kahn 1999; Nieminen 2004). No significant differences were seen in the 
rate of incontinence to flatus or faeces postoperatively between the groups, nor 
in rates of postoperative dyspareunia but the trials were too small for these data 
to be reliable. There were differences between the trials for the outcome 
postoperative complications: in one trial, four women had a haematoma and one 
needed a blood transfusion in the vaginal arm (Kahn 1999) whereas in the other, 
one woman had a wound infection after transanal operation (Nieminen 2004) 
(Comparison 03.13.01).  
Objective 8: posterior vaginal wall repair versus an abdominal posterior 
repair:  
No trials identified. 
Objective 14: posterior vaginal wall repair versus posterior vaginal wall 
repair with mesh reinforcement:  
One trial compared posterior repair with and without mesh reinforcement (Sand 
2001). Rectocele recurrence appeared equally common with and without 
polyglactin (Vicryl) mesh augmentation (7 out of 67 versus 6 out of 65), but the 
confidence intervals were wide (RR 1.13, 95% CI 0.40 to 3.19, Figure 3) (Sand 
2001). No trial reported mesh erosion.  
Another trial compared posterior colporrhaphy, site specific repair and site 
specific repair augmented with porcine small intestine submucosa graft inlay for 
repairing rectoceles (Paraiso 2006). There was no statistical difference in 
objective failure between posterior colporrhaphy and site specific repair (RR 
0.64, 95%CI 0.20 to 2.03, Figure 3) (Paraiso 2006). There was a lower objective 
failure rate at 1 year following the posterior colporrhaphy as compared to porcine 
graft inlay (RR 0.31, 95% CI 0.11 to 0.84, Figure 3) (Paraiso 2006). However, 
there were no differences in subjective report of prolapse symptoms 
(Comparison 03.01.02 and 03). Rates of postoperative dyspareunia were similar 
between posterior colporrhaphy and site specific repair (RR 1.65, 95%CI 0.71 to 
3.81) (Paraiso 2006) and between posterior colporrhaphy and porcine graft 
groups (RR 2.85, 95% CI 0.91 to 8.96) (Paraiso 2006). There were no significant 
differences between the groups in operating time (Comparison 03.11), change in 
haematocrit, postoperative complications (Comparison 03.13), duration of 
hospital stay, postoperative bowel and sexual function or reoperation rate for 
prolapse recurrence (Comparison 03.16). The nature of the different grafts 
utilised in the Sand and Paraiso study did not allow for meta-analysis.  
 
D. Any type of prolapse (Comparisons 04, 05, 06, 07, 08)  




This is one of three reviews of interventions for pelvic organ prolapse and it 
should be viewed in that context. In the other two reviews, no randomised trials 
evaluating either conservative, physical or lifestyle interventions (Hagen 2006) or 
mechanical devices or pessaries (Adams 2004) were identified. 
Amongst the 21 trials that addressed surgical management of pelvic organ 
prolapse, the quality of the trials was variable. All trials reported an objective 
evaluation of the specific pelvic floor defect that was repaired, but full vaginal site 
specific outcomes were only available for seven trials (Colombo 1996a; Colombo 
1997; Colombo 2000; Maher 2004; Weber 2001, Cervigni 2005; Meschia 2004a). 
All but three trials (Brubaker 2006; Cervigni 2005; Jeng 2005) reported median 
follow up of greater than one year but only three trials reported outcomes at 
greater than five years (Colombo 1997; Colombo 2000; Lo 1998).  
Generally, the impact of surgery on associated pelvic floor symptoms including 
bladder, bowel and sexual function, quality of life, cost and patient satisfaction 
were poorly reported. Validated pelvic floor questionnaires were reported in two 
trials (Maher 2004; Roovers 2004), cost issues also by two trialists (Benson 
1996; Maher 2004) and impact of surgery on quality of life and patient 
satisfaction in one trial (Maher 2004). These deficiencies generally reflect the 
difficulties associated with prolapse surgery. One of the principal aims of 
prolapse surgery is to correct the vaginal protrusion and any associated pelvic 
floor dysfunction, but the anatomical correction itself is likely to impact upon 
bladder, bowel and sexual function in unpredictable ways. Until recently, neither 
standardised history, validated pelvic organ prolapse or specific quality of life 
questionnaires or other outcome assessment tools were available.  
It was disappointing that few trials were found which evaluated conservative, 
physical, lifestyle or mechanical means of prolapse treatment (Adams 2004; 
Hagen 2004), and none which compared these interventions with surgery. One 
ongoing trial is comparing different types of sutures (Allahdin 2007).  
Upper vaginal prolapse  
The abdominal sacral colpopexy was associated with a lower rate of recurrent 
vault prolapse (Benson 1996; Maher 2004), reduced grade of residual prolapse 
(Lo 1998), greater length of time taken to recurrence of prolapse (Benson 1996) 
and less dyspareunia (Benson 1996; Lo 1998; Maher 2004) as compared to the 
vaginal sacrospinous colpopexy. The data were too few to assess possible 
differences in satisfaction, bowel outcomes or adverse effects reliably. However, 
the abdominal sacral colpopexy was associated with a longer operating time 
(Benson 1996; Lo 1998; Maher 2004), a longer time for recovery (Maher 2004), 
and it was more expensive (Benson 1996; Maher 2004) than the vaginal 
approach. The finding of less postoperative stress urinary incontinence after the 
abdominal approach must be viewed with caution due to the different continence 
procedures performed in the two trials (as described in the Methodology section). 
The trend towards a lower reoperation rate in the abdominal group did not reach 
statistical significance (Benson 1996, Maher 2004). Culligan 2005 reported that 
there were no recurrent vault prolapses using either abdominal sacral colpopexy 
with monofilament polypropylene mesh or sacral colpopexy using cadaveric 
fascia lata graft inlay (Tutoplast), but there was less recurrence of prolapse at 
any other vaginal site at one year of follow up when mesh was used.  
In a fifth trial, more women needed repeat prolapse surgery after abdominal 
sacral hysteropexy (without hysterectomy), and fewer women had pain, 
overactive bladder symptoms or obstructive micturition symptoms after vaginal 
surgery which included hysterectomy (Roovers 2004). A further trial in which 
women in one arm had uterine preservation reported few relevant outcomes 
(Jeng 2005). However, the clinical relevance of these trials, which compared 
different approaches and uterine preservation in one arm and hysterectomy in 
the other, is debatable. 
One trial was too small to demonstrate a difference in anatomical outcome 
between the vaginal sacrospinous colpopexy and posterior intravaginal 
slingplasty (Meschia 2004a). Although the posterior intravaginal sling was 
quicker to perform and showed a significantly reduced blood loss, it was 
associated with a 9% rate of mesh complications (Meschia 2004a).  
 
Anterior vaginal wall prolapse 
There was some evidence from two small trials that absorbable polyglactin mesh 
(Vicryl) might reduce objective prolapse recurrence compared with anterior repair 
alone (Sand 2001; Weber 2001). A single randomised controlled trial 
demonstrated that the porcine dermis augmentation of the anterior vaginal wall 
might be beneficial in reducing recurrent anterior vaginal wall prolapse (Meschia 
2007). Cadaveric fascia lata (Tutoplast) augmentation of anterior vaginal wall 
was not beneficial in reducing recurrent anterior vaginal wall prolapse (Gandhi 
2005). Two further RCTs compared various mesh augmentations. In a single 
RCT (De Ridder 2004) it was demonstrated that porcine dermis reduces 
recurrent anterior vaginal wall prolapse compared to polyglactin augmentation 
whereas Prolene Soft and porcine dermis inlays resulted in similar failure rates 
(Cervigni 2005). It is pertinent, however, that of these four types of mesh or 
grafts, only one (Prolene Soft) was non-absorbable, and only used in 36 women 
in one trial (Cervigni 2005). Data for other symptoms were not reported. 
Importantly, long-term outcome data were not available, in particular regarding 
adverse effects such as mesh erosion. 
These four studies evaluated five interventions, anterior colporrhaphy and four 
different grafts, making a meta-analysis inappropriate. The heterogenicity of the 
meshes used made the comparison of mesh complications impossible. There 
was a lack of information on functional (subjective) outcomes.  
Julian et al found in a non-randomised prospective study that in women who had 
undergone at least two previous vaginal repairs, the overlaying of a Marlex 
(Bard) mesh to the anterior vaginal wall repair was associated with lower 
recurrence rates of cystocele from 33% to 0% (Julian 1996). The Marlex mesh 
was associated with a mesh erosion rate of 25% (Julian 1996). Flood et al, in a 
retrospective review of 142 women with Marlex mesh augmentation of anterior 
vaginal wall repair, reported a 100% success rate for cystoceles at 3.2 years and 
a mesh erosion rate of only 2% (Flood 1998).  
In one other trial concerning women all of whom had stress urinary incontinence 
as well as prolapse, Burch colposuspension was subjectively better at curing the 
incontinence and anterior repair was better for the prolapse (Colombo 2000) but 
the trial was too small to judge whether this affected subsequent reoperation 
rates or the effect on other aspects of bladder, bowel or sexual function.  
 
Posterior vaginal wall prolapse   
Posterior vaginal wall repair performed better than the transanal repair of 
rectocele in terms of a significantly lower recurrence rate of posterior vaginal wall 
prolapse in two trials, despite a higher blood loss and greater use of pain relief 
(Kahn 1999; Nieminen 2004). However, the data were too few to comment on 
clinical outcomes such as flatus or faecal incontinence, or dyspareunia. More 
women had difficulties in bowel evacuation after transanal operation but this did 
not reach statistical significance. In total, five serious adverse effects were 
reported amongst the 87 women in the two trials.  
The trials evaluating mesh augmentation of posterior repair were too small to 
address this question reliably (Paraiso 2006; Sand 2001), although no woman 
reported mesh erosion (Sand 2001). In one single well conducted study the 
posterior colporrhaphy was demonstrated to have a lower failure rate as 
compared to the site specific repair with Porcine small intestine submucosa graft 
for rectoceles. There were no significant other differences between the posterior 
colporrhaphy, site specific repair or site specific repair augmented with Porcine 
small intestine submucosa in terms of perioperative and postoperative morbidity, 
functional outcomes, quality of life and bowel and sexual function (Paraiso 2006). 
Authors' conclusions 
Implications for practice 
The data from randomised trials are currently insufficient to guide practice.  
The following conclusions from the review relate to the three areas of surgical 
management of pelvic organ prolapse where at least two randomised controlled 
trials have been completed: 
• Abdominal sacral colpopexy was associated with a lower rate of recurrent 
vault prolapse and less dyspareunia than the vaginal sacrospinous 
colpopexy. The abdominal colpopexy had a longer operating time, longer 
recovery and higher cost than the vaginal surgery. Data on the subjective 
success rate, patient satisfaction and impact of the surgery on quality of 
life were too few for reliable conclusions.  
• The limited evidence suggested that the use of an absorbable polyglactin 
mesh inlay or absorbable porcine dermis at the time of anterior vaginal 
wall repair may reduce the risk of recurrent cystocele, but information on 
the effects on bladder, bowel or sexual function are limited and 
inconclusive.  
• The limited evidence suggested that posterior vaginal wall repair may 
have a better anatomical success rate than transanal repair in the 
management of posterior vaginal wall prolapse but the clinical effects are 
uncertain.  
 
There were insufficient data to allow evaluation of the impact of prolapse surgery 
on continence issues but limited information suggested that concomitant TVT or 
Burch colposuspension might reduce postoperative incontinence rates: this 
benefit needs to be balanced against possible differences in costs and adverse 
effects. There was generally a lack of information on the impact of the surgery 
on quality of life and cost issues.  
Implications for research 
None of the objectives prestated in the protocol for this review have been 
satisfactorily addressed, and all would benefit from testing in further good 
quality randomised trials.  
More broadly, further evidence on the surgical management of pelvic organ 
prolapse should include but not be limited to the following: 
• Upper vaginal prolapse: vaginal surgery (e.g. vaginal hysterectomy, 
cervical amputation, uterosacral ligament plication, posterior 
intravaginal slingplasty or sacrospinous colpopexy); abdominal surgery 
(e.g. open or laparoscopic sacral colpopexy, abdominal hysterectomy); 
laparoscopic pelvic floor repair; and the use of mesh or grafts.  
• Anterior vaginal wall prolapse: vaginal surgery (e.g. anterior vaginal wall 
repair, vaginal paravaginal repair); and open or laparoscopic abdominal 
surgery (e.g. paravaginal repair); and the use of mesh or grafts.  
• Posterior vaginal wall prolapse: vaginal surgery (e.g. midline posterior 
vaginal wall repair, fascial repairs); the abdominal or laparoscopic 
approach to rectoceles; and the use of mesh or grafts.  
• Evaluation of different types of sutures, mesh and grafts.  
 
Other trials relating to pelvic organ prolapse should include comparisons with 
conservative treatment, including but not limited to, pelvic floor exercises, 
lifestyle changes and mechanical devices (pessaries).  
The challenge in prolapse surgery is that while the prolapse itself may cause 
difficulties with bladder, bowel and sexual function, surgical correction may 
also affect these functions in unpredictable ways. Therefore, all trials need to 
include subjective, objective and patient determined outcomes, and the direct 
interaction with bladder, bowel and sexual function must be measured. The 
impact of interventions should also be assessed by utilising validated pelvic 
floor and quality of life questionnaires, morbidity and cost analysis. Ideally, 
long term outcomes should be reported at least at two and five years after 
surgery.  
The results of a Cochrane Review can be interpreted differently, depending 
on people's perspectives and circumstances.  Please consider the 
conclusions presented carefully.  They are the opinions of review authors, 
and are not necessarily shared by The Cochrane Collaboration. 
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